Minimal immune response after transplantation of a cryopreserved human amniotic membrane on the ocular surface
Abstract
Introduction: Human amniotic membrane (hAM) is considered to have low immunogenicity since Akle et al. reported no anti-HLA antibodies (Abs) in four volunteers after subcutaneous grafting of fresh hAM in 1981. But the sensitivity of the detection methods has significantly improved since then. Furthermore, hAM graft is a massive local input of allogenic HLA-G whose potential immunogenicity has never been assessed. The objective of this study was to look for the presence of anti-HLA class I, II, and anti HLA-G Abs at 1 and 3 months after hAM transplantation on the ocular surface. Material and methods: Twenty-three patients who required a hAM graft on the ocular surface (cornea and/or conjunctiva) for any indication were enrolled in this prospective clinical study. Sera were collected on the day of transplantation and at 1- and 3-months post-transplantation (M0, M1, M3). Anti-HLA class I, and II Abs were assessed using the Luminex® Single Antigen technique. Anti HLA-G Abs were assessed using an in-house ELISA-based detection assay, derived from the Monoclonal Antibody specific Immobilization of Platelet Antigen (MAIPA) assay. Results: Ab apparition after transplantation. Six patients showed a significant increase of preformed Abs MFI (>50 %) during follow up although transient in one out of six. No anti-HLA-G Abs were identified before or after hAM transplantation. Conclusion: This is the first study to investigate anti-HLA class I, II, and anti HLA-G Abs in a clinical setting after cryopreserved hAM transplantation. The main finding of this study is the minimal humoral immune response in our patients, supporting the immunological safety of the procedure and the excellent clinical tolerance reported across various indications over decades of use.
Related
- Reassessing the cryopreserved human amniotic membrane's low immunogenicity due to advances in histocompatibility
- Recurrence After Conjunctival Autograft versus Amniotic Membrane Transplantation for Primary Pterygium: A Retrospective Kaplan-Meier Cohort Study
- Case Report: Ribociclib-associated bilateral neurotrophic keratitis requiring amniotic membrane transplantation during adjuvant treatment of early breast cancer
- Vision-Related Quality of Life and Dry Eye Symptoms After Treatment with Lyophilized Amniotic Membrane Eye Drops: A Secondary Analysis of a Prospective Cohort Study
- Late-onset spontaneous chorioamniotic membrane separation mimicking amniotic band sequence with rapid progression to preterm premature rupture of membranes
BibTeX
@article{baudey2026minimal,
title = {{Minimal immune response after transplantation of a cryopreserved human amniotic membrane on the ocular surface}},
author = {Jean-Baptiste Baudey and Lauriana Solecki and Christophe Picard and Bastien Mathéaud and Pauline Jamain and Isabelle Jollet and Lucas Hubert and Alain Coaquette and Adeline Desanlis and Xavier Lafarge and Pascal Pedini and Florelle Gindraux},
journal = {Materials Today Bio},
year = {2026},
month = sep,
doi = {10.1016/j.mtbio.2026.102821},
url = {https://hal.science/hal-05756959v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Minimal immune response after transplantation of a cryopreserved human amniotic membrane on the ocular surface
AU - Jean-Baptiste Baudey
AU - Lauriana Solecki
AU - Christophe Picard
AU - Bastien Mathéaud
AU - Pauline Jamain
AU - Isabelle Jollet
AU - Lucas Hubert
AU - Alain Coaquette
AU - Adeline Desanlis
AU - Xavier Lafarge
AU - Pascal Pedini
AU - Florelle Gindraux
PY - 2026
DA - 2026/09/21
JO - Materials Today Bio
DO - 10.1016/j.mtbio.2026.102821
UR - https://hal.science/hal-05756959v1
AB - Introduction: Human amniotic membrane (hAM) is considered to have low immunogenicity since Akle et al. reported no anti-HLA antibodies (Abs) in four volunteers after subcutaneous grafting of fresh hAM in 1981. But the sensitivity of the detection methods has significantly improved since then. Furthermore, hAM graft is a massive local input of allogenic HLA-G whose potential immunogenicity has never been assessed. The objective of this study was to look for the presence of anti-HLA class I, II, and anti HLA-G Abs at 1 and 3 months after hAM transplantation on the ocular surface. Material and methods: Twenty-three patients who required a hAM graft on the ocular surface (cornea and/or conjunctiva) for any indication were enrolled in this prospective clinical study. Sera were collected on the day of transplantation and at 1- and 3-months post-transplantation (M0, M1, M3). Anti-HLA class I, and II Abs were assessed using the Luminex® Single Antigen technique. Anti HLA-G Abs were assessed using an in-house ELISA-based detection assay, derived from the Monoclonal Antibody specific Immobilization of Platelet Antigen (MAIPA) assay. Results: Ab apparition after transplantation. Six patients showed a significant increase of preformed Abs MFI (>50 %) during follow up although transient in one out of six. No anti-HLA-G Abs were identified before or after hAM transplantation. Conclusion: This is the first study to investigate anti-HLA class I, II, and anti HLA-G Abs in a clinical setting after cryopreserved hAM transplantation. The main finding of this study is the minimal humoral immune response in our patients, supporting the immunological safety of the procedure and the excellent clinical tolerance reported across various indications over decades of use.
SN - 2590-0064
ER -